Drug Search Results
More Filters [+]

Molidustat

Alternative Names: molidustat, bay 85-3934, molidustat(bay85-3934), bay85-3934
Latest Update: 2024-09-13
Latest Update Note: Clinical Trial Update

Product Description

Molidustat is a compound which inhibits hypoxia inducible factor prolyl hydroxylase (HIF-PH) activity. HIF-PH inhibitors are being investigated as novel therapies for anemia, especially anemia caused by chronic kindney disease (CKD). It is hoped that HIF-PH inhibitors will provide a more effective alternative to the use of erythropoetin replacement therapy plus iron supplementation in CKD patients. (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8456)

Mechanisms of Action: HIF Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Japan

Approved Indications: None

Known Adverse Events: None

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Molidustat

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Acute Myeloid Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MOLIVO-1

P2

Active, not recruiting

Acute Myeloid Leukemia

2026-05-08

Recent News Events